REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers. (2023)
Attributed to:
Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.cct.2022.107030
PubMed Identifier: 36519749
Publication URI: http://europepmc.org/abstract/MED/36519749
Type: Journal Article/Review
Volume: 124
Parent Publication: Contemporary clinical trials
ISSN: 1551-7144